Haemonetics Corporation (HAE) - Cash per Share

Haemonetics Corporation generates revenue by developing plasma collection and blood purification systems. This chart from the GURU.Markets portal illustrates cash per share over the period, where 5.74 represents the latest metric level. Profitability is driven by high-margin consumables paired with low-cost equipment, while business resilience is supported by non-cyclical demand within the hematology sector.
Analytical breakdowns for Haemonetics Corporation

Amid fierce competition for clinic contracts and the risk of technological displacement, Haemonetics Corporation (HAE) requires a liquid reserve for R&D and the protection of its market positions. Analyzing this chart of cash per share, an investor can see the actual remaining free funds, which serve as the foundation for capitalization and a guarantee of financial stability when discounting future cash flows.